drugset / Trial / NCT03278028

A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts

NCT03278028

Phase 2 Completed 159 enrolled Aclaris Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study is to evaluate the effectiveness of A-101 compared to Vehicle when applied to 1 Target common wart on the trunk or extremities twice a week.

Timeline

Start
2017-07-13
Primary completion
2018-03-01
Completion
2018-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydrogen Peroxide Small molecule Topical

Indications